Clinical trials Below are current clinical trials.83 studies in Radiology (open studies only). Filter this list of studies by location, status and more. A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with GRPR+, ER+, HER2- metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibito Rochester, Minn. The purpose of this study is to determine the recommended doses (RD) and dosing regimens of [ 177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor. In the phase II part, to evaluate the preliminary antitumor activity of two different doses/regimens of [177Lu]Lu-NeoB in combination with capecitabine (dose optimization). A Study to Predict Sepsis-Associated Acute Kidney Injury by Assessing Renal Microvascular Blood Flow and Elasticity with Contrast-Enhanced Ultrasonography and Ultrasound Elastogram Rochester, Minn. The purpose of this study is to assess kidney microcirculation using contrast-enhanced ultrasonography associated with kidney ultrasound elastography among patients who are at risk of sepsis-associated acute kidney injury provides strong predictive ability for AKI and potential therapeutic targets. EF-41/KEYNOTE D58: Phase 3 Study Of Optune Concomitant With Temozolomide Plus Pembrolizumab In Newly Diagnosed Glioblastoma Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS). Pagination Clinical studies PrevPrevious Page Go to page 77 Go to page 88 Go to page 99 Request an appointment Expertise & rankingsResearch Feb. 14, 2026 Share on: FacebookTwitter RadiologySectionsOverviewTests & proceduresConditions treatedDoctorsDoctors by location and specialtySpecialty groupsExpertise & rankingsClinical trialsResearchCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewTests & proceduresConditions treatedDoctorsDoctors by location and specialtySpecialty groupsExpertise & rankingsClinical trialsResearchCosts & insuranceNews from Mayo ClinicReferrals ORG-20469617 Medical Departments & Centers Radiology